Increased<i>TBX6</i>gene dosages induce congenital cervical vertebral malformations in humans and mice

Xiaojun Ren,Nan Yang,Nan Wu,Ximing Xu,Weisheng Chen,Ling Zhang,Yingping Li,Ren-Qian Du,Shuangshuang Dong,Sen Zhao,Shuxia Chen,Li-Ping Jiang,Lianlei Wang,Jianguo Zhang,Zhihong Wu,Li Jin,Guixing Qiu,James R Lupski,Jiangang Shi,Feng Zhang,Pengfei Liu
DOI: https://doi.org/10.1136/jmedgenet-2019-106333
2019-01-01
Journal of Medical Genetics
Abstract:BackgroundCongenital vertebral malformations (CVMs) manifest with abnormal vertebral morphology. Genetic factors have been implicated in CVM pathogenesis, but the underlying pathogenic mechanisms remain unclear in most subjects. We previously reported that the human 16p11.2 BP4-BP5 deletion and its associatedTBX6dosage reduction caused CVMs. We aim to investigate the reciprocal 16p11.2 BP4-BP5 duplication and its potential genetic contributions to CVMs.Methods and resultsPatients who were found to carry the 16p11.2 BP4-BP5 duplication by chromosomal microarray analysis were retrospectively analysed for their vertebral phenotypes. The spinal assessments in seven duplication carriers showed that four (57%) presented characteristics of CVMs, supporting the contention that increasedTBX6dosage could induce CVMs. For further in vivo functional investigation in a model organism, we conducted genome editing of the upstream regulatory region of mouseTbx6using CRISPR-Cas9 and obtained three mouse mutant alleles (Tbx6up1toTbx6up3) with elevated expression levels ofTbx6. Luciferase reporter assays showed that theTbx6up3allele presented with the 160% expression level of that observed in the reference (+) allele. Therefore, the homozygousTbx6up3/up3mice could functionally mimic theTBX6dosage of heterozygous carriers of 16p11.2 BP4-BP5 duplication (approximately 150%, ie, 3/2 gene dosage of the normal level). Remarkably, 60% of theTbx6up3/up3mice manifested with CVMs. Consistent with our observations in humans, the CVMs induced by increasedTbx6dosage in mice mainly affected the cervical vertebrae.ConclusionOur findings in humans and mice consistently support that an increasedTBX6dosage contributes to the risk of developing cervical CVMs.
What problem does this paper attempt to address?